Mitral valve prolapse affects roughly 2% to 3% of the general population, making it one of the most common heart valve conditions. That number has actually come down over the years. Older studies from the 1970s through the 1990s estimated prevalence as high as 5% to 10%, but improved imaging standards have since cut those figures significantly.
Why the Numbers Changed
For decades, mitral valve prolapse was widely quoted as affecting 5% or more of the population. A comprehensive review published in 2024 helps explain the discrepancy. Studies conducted before 1999, using older and less specific ultrasound criteria, found a pooled prevalence of 7.8%. Studies conducted from 1999 onward, using stricter diagnostic standards, found a pooled prevalence of just 2.2%. The older numbers were inflated by less precise imaging, referral bias (studying hospital patients rather than the general public), and diagnostic criteria that were too broad.
Today, the condition is diagnosed when an echocardiogram shows the mitral valve leaflets bulging at least 2 mm back into the upper heart chamber during each heartbeat. When the leaflets are also noticeably thickened (at least 5 mm), it’s considered “classic” prolapse. A large community study found that about 1.3% of people had classic prolapse and another 1.1% had the non-classic form, where the leaflets bulge but remain thin. The distinction matters because classic prolapse carries a higher chance of complications down the road.
Who Gets It
Women are diagnosed with mitral valve prolapse more often than men and tend to be diagnosed at a younger age. However, the type of prolapse differs between the sexes. Women more commonly have a benign form involving generalized thickening of the valve tissue. Men are more likely to develop the structural changes that eventually lead to significant leaking and surgical repair.
Age plays a role too. A 2025 meta-analysis found prevalence rates of 0.5% in newborns, 1.8% in children, 2.7% in adolescents, and 2.0% in adults overall. Within the adult population, older adults had a significantly higher prevalence (about 2.9%) compared to younger adults (0.7%). So while the condition can appear at any age, including infancy, it becomes more common as people get older.
There’s also a strong hereditary component. An estimated 20% to 35% of cases have a familial or genetic basis, meaning if a close relative has the condition, your own risk is meaningfully higher.
What Happens for Most People
The majority of people with mitral valve prolapse never develop serious problems. A community study from Olmsted County, Minnesota, followed 833 people diagnosed with asymptomatic prolapse and found that roughly half fell into a low-risk category. Those low-risk individuals had a 10-year survival rate comparable to the general population, with cardiovascular complications occurring at a rate of just 0.5% per year and prolapse-related events at only 0.2% per year. For these people, the condition is essentially a structural quirk that requires monitoring but not treatment.
Many people with prolapse do experience symptoms like heart palpitations, chest discomfort, fatigue, or lightheadedness, but these symptoms are often manageable and don’t indicate dangerous valve deterioration. The key factors that separate low-risk from higher-risk prolapse include how much the valve leaks, how thick the leaflets are, and whether the heart chambers have started to enlarge in response.
When Complications Develop
The most serious complication is progressive mitral regurgitation, where the valve leaks enough blood backward that the heart has to work harder and eventually needs surgical repair. The risk of reaching that point is minimal before age 50 but rises steeply after that, particularly in men. By age 70, roughly 1 in 28 men with prolapse will have needed surgery for severe regurgitation. Women face less than half that risk.
Infective endocarditis, a dangerous infection of the valve itself, is another recognized complication. People with mitral valve prolapse face about 8 times the risk of endocarditis compared to the general population, translating to roughly 87 cases per 100,000 person-years. Over a 15-year period after diagnosis, the cumulative risk is about 1.1%. That’s elevated relative to the general population but still quite low in absolute terms.
Classic vs. Non-Classic Prolapse
The split between the two subtypes is roughly even. In the large Framingham Heart Study, 1.3% of participants had classic prolapse (thickened, redundant leaflets) and 1.1% had non-classic prolapse (leaflets that bulge but stay thin and structurally normal). Classic prolapse is the form more closely linked to progressive valve leaking, enlargement of the heart chambers, and eventual need for surgical intervention. Non-classic prolapse tends to follow a benign course, with complication rates closer to the general population.
If you’ve been told you have mitral valve prolapse, the specific subtype and degree of valve leaking matter far more than the diagnosis alone. For the majority of the estimated 2% to 3% of people who have this condition, long-term outcomes are excellent.